NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that in preparation of a scheduled pre-pre-IND meeting discussion with the FDA, the company has retained the services of the Director of Cell and Gene Therapies of the Biologics Consulting Group, Inc., Dr. Andra E. Miller, as consultant to handle the company’s FDA interactions. The purpose of the pre-pre-IND meeting with the FDA is to discuss BrainStorm’s planned preclinical strategy in support of the company’s Investigative New Drug application (IND). Dr. Miller will serve as BrainStorm’s advisor towards the regulatory process with the FDA, and will lead BrainStorm’s regulatory efforts for its adult stem cell technologies and therapies for neurodegenerative diseases.
